Protagen, Scienion Ink Partnership | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Protagen today announced that Scienion will produce protein microarray batches of more than 1,000 arrays for Protagen for the clinical validation of biomarker panels.

In addition, under a strategic partnership, the two Dortmund, Germany-based firms will jointly evaluate new platforms for multiplexed analytics and co-develop new approaches up to proof-of-concept levels.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.